| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 5.1MM | -15% |
| Gross Profit | 3.5MM | -19% |
| Cost Of Revenue | 1.6MM | -5% |
| Operating Income | -2MM | +84% |
| Operating Expenses | 5.5MM | +2% |
| Net Income | -2MM | - |
| R&D | 717.3K | +27% |
| G&A | 4.8MM | -0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
BOSTON, March 28, 2024--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors.
Director Thomas Kirk has recently increased his stake in Myomo Inc (AMEX:MYO) by purchasing 50,000 shares of the company's stock, as indicated by a SEC Filing dated March 14, 2024.
Myomo, Inc. (AMEX:MYO) Q4 2023 Earnings Call Transcript March 7, 2024 Myomo, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome to the Myomo Fourth Quarter 2023 Earnings Call. All participants will be in a listen-only mode. […]
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -40% and 1.19%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
BOSTON, March 07, 2024--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2023.
BOSTON, March 01, 2024--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that on February 29, 2024, the Centers for Medicare & Medicaid Services (CMS) posted the final Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) fee schedule payment rates for the MyoPro®.
BOSTON, February 29, 2024--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and fiscal year ended December 31, 2023 on March 7, 2024.
BOSTON, January 19, 2024--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has closed its previously announced registered direct offering of its common stock, priced at-the-market with certain new and existing institutional investors as well as certain insiders of the Company, for the purchase and sale of 1,578,948 s
BOSTON, January 17, 2024--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has entered into securities purchase agreements with certain new and existing institutional investors as well as certain insiders of the Company for the purchase and sale of 1,578,948 shares of common stock (or common stock equivalents in lieu
BOSTON, January 17, 2024--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced preliminary revenue and operating metrics for the fourth quarter of 2023.